This is too long to fit in one post. Anyone know anything about this?
COVID-19 Anti-Trust Argument
Some of this information was submitted to the Office of the Inspector General for the United States Department of Health and Human Services on April 22, 2020
Request for Investigation - Possible Sherman Act Violation
Citizens of the United States of America
v.
United States Department of Health and Human Services Centers for Disease Control and Prevention
Robert R Redfield, et al.
National Institute of Allergy and Infectious Diseases
Anthony Stephen Fauci, et al.
Governors of All States Issuing Executive Orders abridging the 1st Amendment of the Constitution
University of North Carolina, Chapel Hill
Professor Ralph Baric, et al.
And unknown Parties
On April 25, 2003, the United States Department of Health and Human Services Centers for Disease Control and Prevention (hereinafter, “CDC”) filed an application for a United States (Application Number US46592703P, subsequently issued as U.S. Patent 7,776,521) entitled “Coronavirus isolated from humans”. Claim 3 –A method of detecting a severe acute respiratory syndrome-associated coronavirus (SARS-CoV) in a sample…; and, Claim 4 - A kit for detecting a severe acute respiratory syndrome-associated coronavirus (SARS-CoV) in a sample…, provided the CDC with a statutory market exclusion right the detection of and sampling for severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Securing this right afforded the CDC exclusive right to research, commercially exploit, or block others from conducting activities involving SARS-CoV. On September 24, 2018, the CDC failed to pay the required maintenance fees on this patent and their rights expired.
From April 2003 until September 2018, the CDC owned SARS-CoV, its ability to be detected and the ability to manufacture kits for its assessment. During this 15-year period, the effect of the grant of this right – ruled unconstitutional in 2013 by the United States Supreme Court in the case of Association for Molecular Pathology et al. v. Myriad Genetics – meant that the commercial exploitation of any research or commercial activity in the United States involving SARS-CoV would constitute an infringement of CDC’s illegal patent.
It appears that, during the period of patent enforcement and after the Supreme Court ruling confirming that patents on genetic material was illegal, the CDC and National Institute of Allergy and Infectious Diseases led by Anthony Fauci (hereinafter “NIAID” and "Dr Fauci", respectively) entered into trade among States (including, but not limited to working with Ecohealth Alliance Inc.) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy of Sciences) through the 2014 et seq National Institutes of Health Grant R01AI110964 to exploit their patent rights.
It further appears that, during the period of patent enforcement and after the Supreme Court ruling confirming that patents on genetic material were illegal, the CDC and National Institute of Allergy and Infectious Diseases (hereinafter “NIAID”) entered into trade among States (including, but not limited to working with University of North Carolina, Chapel Hill) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy of Sciences represented by Zheng-Li Shi) through U19AI109761 (Ralph S. Baric), U19AI107810 (Ralph S. Baric), and National Natural Science Foundation of China Award 81290341 (Zheng-Li Shi) et al.
It further appears that, during the period of patent enforcement and after the Supreme Court ruling confirming that patents on genetic material was illegal, the CDC and NIAID entered into trade among States (including, but not limited to working with University of North Carolina, Chapel Hill) and with foreign nations to conduct chimeric construction of novel coronavirus material with specific virulence properties prior to, during, and following the determination made by the National Institutes for Health in October 17, 2014 that this work was not sufficiently understood for its biosecurity and safety standards.
(1)